An Open Label Study of SC-006 in Subjects With Advanced Cancer

Next Previous
Trial Profile

An Open Label Study of SC-006 in Subjects With Advanced Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Apr 2018

At a glance

  • Drugs SC 006 (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Sponsors AbbVie

    • Most Recent Events

    • 28 Jun 2017 Planned End Date changed from 19 Feb 2021 to 22 Dec 2020.
    • 30 Mar 2017 Planned End Date changed from 1 Jan 2021 to 1 Feb 2021.
    • 30 Mar 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top